apalutamide

J&J gets first-of-its-kind prostate cancer approval
J&J gets first-of-its-kind prostate cancer approval
Biopharma Dive
JNJ
apalutamide
prostate cancer
Flag link:
As CAR-Ts go from candidates to brands, what's the marketing strategy?
As CAR-Ts go from candidates to brands, what's the marketing strategy?
Medical Marketing and Media
CAR-T
drug marketing
JCAR017
Juno Therapeutics
Celgene
bb2121
Bluebird Bio
apalutamide
Janssen
Flag link:
Strong data lift profile of J&J's cancer drug apalutamide
Strong data lift profile of J&J's cancer drug apalutamide
Biopharma Dive
JNJ
apalutamide
prostate cancer
Flag link:
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
With Pfizer in hot pursuit, J&J loses a critical patent fight as it scrambles for a new prostate cancer drug OK
Endpoints
Pfizer
JNJ
patents
Zytiga
Xtandi
prostate cancer
apalutamide
Flag link:
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate
Endpoints
drug launches
Bictegravir/F/TAF
Gilead Sciences
semaglutide
Novo Nordisk
epacadostat
Incyte
Rova-T
AbbVie
ozanimod
Celgene
apalutamide
JNJ
Elagolix
AVXS-101
AveXis
lanadelumab
Shire
Epidiolex
GW Pharma
Flag link:
J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide
J&J takes another big step forward with next-gen prostate cancer blockbuster apalutamide
Endpoints
JNJ
prostate cancer
apalutamide
Flag link:
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Biogen
aducanumab
JNJ
apalutamide
Eli Lilly
abemaciclib
AbbVie
Rova-T
Celgene
ozanimod
Flag link: